Synta And Roche Agree To Co-Develop Anti-Inflammatory Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal for Synta’s CRAC channel inhibitor brings $25 million upfront plus potential for $1 billion in milestones.
You may also be interested in...
Elesclomol's Phase III Fizzle Leaves Synta In Need Of Alternatives
Suspension of Synta/GlaxoSmithKline's Phase III oncology candidate elesclomol amid signs of higher mortality has left developer Synta with a gaping late-stage pipeline hole and in need of a new business plan
Elesclomol's Phase III Fizzle Leaves Synta In Need Of Alternatives
Suspension of Synta/GlaxoSmithKline's Phase III oncology candidate elesclomol amid signs of higher mortality has left developer Synta with a gaping late-stage pipeline hole and in need of a new business plan
Elesclomol’s Phase III Fizzle Leaves Synta In Need of Plan B
News on melanoma could put the biotech’s lucrative partnership with GlaxoSmithKline in jeopardy.